AdvaMed, the Advanced Medical Technolgy Association, appointed James B. Smith vice president of federal government relations.
AltaRex Corp., of Waltham, Mass., appointed James Levin vice president, manufacturing and development, and Sondra Henrichon director, investor relations and corporate communications.
Antex Biologics Inc., of Gaithersburg, Md., appointed Stephen N. Keith president and chief operating officer.
Avigen Inc., of Alameda, Calif., appointed Janice Castillo vice president of regulatory affairs.
Axxima Pharmaceuticals AG, of Munich, Germany, elected to its supervisory board Heinrich Kuhn, Alexandra Goll, Jerry Hook, David Knowles, Sir Mark Richmond and Axel Ullrich.
Biogen Inc., of Cambridge, Mass. appointed Peter N. Kellogg vice president of finance and chief financial officer.
California Healthcare Institute, of La Jolla, Calif., elected to its board of directors Fabrizio Bonanni, Amgen Inc.'s senior vice president, quality control, quality assurance, regulatory compliance and environmental health and safety.
Cell Pathways Inc., of Horsham, Pa., appointed Robert E. Bellet senior vice president, clinical and regulatory affairs.
Collateral Therapeutics Inc., of San Diego, appointed to its scientific advisory board Michael D. Schneider.
Cortex Pharmaceuticals Inc., of Irvine, Calif., promoted Gary Rogers to senior vice president, pharmaceutical research.
Cubist Pharmaceuticals Inc., of Cambridge, Mass., appointed Robert J. McCormack senior vice president of drug development.
DNA Sciences, of Mountain View, Calif., named Raymond White chief scientific officer.
Entelos Inc., of Menlo Park, Calif., named Craig H. Shaffer managing director of professional services.
Entropin Inc., of Indio, Calif., appointed to its board of directors Paul Maier, senior vice president and chief financial officer of Ligand Pharmaceuticals Inc.
Epix Medical Inc., of Cambridge, Mass., promoted Pamela E. Carey to vice president of finance and administration and chief financial officer.
Exten Industries Inc., of San Diego, elected Gregory F. Szabo chairman and chief executive officer.
Forbes Medi-Tech Inc., of Vancouver, British Columbia, named Ian Bradley chief financial officer and Charles Butt senior vice president of commercial operations.
GenStar Therapeutics, of San Diego, appointed Connie J. Kohne vice president of regulatory affairs and corporate quality.
Heska Corp., of Fort Collins, Col., elected to its board of directors William A. Aylesworth and named him chairman of the audit committee.
Human Gene Therapy, published by Mary Ann Liebert Inc., of Larchmont, N.Y., named Mark Kay, of the Stanford University School of Medicine, associate editor.
Ilex Oncology Inc., of San Antonio, Texas, appointed Ze'ev Shaked president of Ilex Products Inc., a subsidiary company.
InKine Pharmaceutical Company Inc., of Blue Bell, Pa., appointed Monroe I. Klein vice president of regulatory affairs, Judith Heyer Murphy executive director of clinical affairs and Jeffrey S. Arcara director of marketing.
Introgen Therapeutics Inc., of Austin, Texas, appointed to its board of directors William H. Cunningham, former CEO of the University of Texas System.
Luminex Corp., of Chapel Hill, N.C., named to its board of directors William L. Roper, dean of the University of North Carolina at Chapel Hill School of Public Health.
Lynx Therapeutics Inc., of Hayward, Calif., elected to its board of directors genomics pioneer Leroy Hood.
MetaMorphix Inc., of Baltimore, named to its board of directors John R. Block, president of Food Distributors International and former U.S. Secretary of Agriculture; and Gerald Welch, former executive vice president, Allied Businesses, The Upjohn Co.